ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET -Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence von Wang, Jieyi, Anderson, Mark G, Oleksijew, Anatol, Vaidya, Kedar S, Boghaert, Erwin R, Tucker, Lora, Zhang, Qian, Han, Edward K, Palma, Joann P, Naumovski, Louie, Reilly, Edward B

Volltext

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer von Wolf, Jürgen, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B, Groen, Harry J.M, Tan, Daniel S.W, Hida, Toyoaki, de Jonge, Maja, Orlov, Sergey V, Smit, Egbert F, Souquet, Pierre-Jean, Vansteenkiste, Johan, Hochmair, Maximilian, Felip, Enriqueta, Nishio, Makoto, Thomas, Michael, Ohashi, Kadoaki, Toyozawa, Ryo, Overbeck, Tobias R, de Marinis, Filippo, Kim, Tae-Min, Laack, Eckart, Robeva, Anna, Le Mouhaer, Sylvie, Waldron-Lynch, Maeve, Sankaran, Banu, Balbin, O. Alejandro, Cui, Xiaoming, Giovannini, Monica, Akimov, Mikhail, Heist, Rebecca S

Volltext

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression von Awad, Mark M, Oxnard, Geoffrey R, Jackman, David M, Savukoski, Daniel O, Hall, Dimity, Shivdasani, Priyanka, Heng, Jennifer C, Dahlberg, Suzanne E, Jänne, Pasi A, Verma, Suman, Christensen, James, Hammerman, Peter S, Sholl, Lynette M

Volltext

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON von Hartmaier, Ryan J, Markovets, Aleksandra A, Ahn, Myung Ju, Sequist, Lecia V, Han, Ji-Youn, Cho, Byoung Chul, Yu, Helena A, Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong-Seok, Su, Wu-Chou, Kowalski, Dariusz M, Orlov, Sergey, Ren, Song, Frewer, Paul, Ou, Xiaoling, Cross, Darren A E, Kurian, Nisha, Cantarini, Mireille, Jänne, Pasi A

Volltext

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study von Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki

Volltext

Fragmentation Chemistry of [Met-Gly]•+, [Gly-Met]•+, and [Met-Met]•+ Radical Cations von Lau, Justin Kai-Chi, Lo, Seydina, Zhao, Junfang, Siu, K. W. Michael, Hopkinson, Alan C.

Volltext

Fishmeal levels can be successfully reduced in white shrimp (Litopenaeus vannamei) if supplemented with DL‐Methionine (DL‐Met) or DL‐Methionyl‐DL‐Methionine (Met‐Met) von Xie, J.‐J., Lemme, A., He, J.‐Y., Yin, P., Figueiredo‐Silva, C., Liu, Y.‐J., Xie, S.‐W., Niu, J., Tian, L.‐X.

Volltext

MET-dependent solid tumours — molecular diagnosis and targeted therapy von Guo, Robin, Luo, Jia, Chang, Jason, Rekhtman, Natasha, Arcila, Maria, Drilon, Alexander

Volltext

MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance von Guo, Robin, Offin, Michael, Brannon, A Rose, Chang, Jason, Chow, Andrew, Delasos, Lukas, Girshman, Jeffrey, Wilkins, Olivia, McCarthy, Caroline G, Makhnin, Alex, Falcon, Christina, Scott, Kerry, Tian, Yuan, Cecchi, Fabiola, Hembrough, Todd, Alex, Deepu, Shen, Ronglai, Benayed, Ryma, Li, Bob T, Rudin, Charles M, Kris, Mark G, Arcila, Maria E, Rekhtman, Natasha, Paik, Paul, Zehir, Ahmet, Drilon, Alexander

Volltext

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations von Albers, Joachim, Friese-Hamim, Manja, Clark, Anderson, Schadt, Oliver, Walter-Bausch, Gina, Stroh, Christopher, Johne, Andreas, Karachaliou, Niki, Blaukat, Andree

Volltext

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells von TROIANI, Teresa, MARTINELLI, Erika, DE PALMA, Raffaele, D'AIUTO, Elena, BERRINO, Liberato, BIANCO, Roberto, CIARDIELLO, Fortunato, NAPOLITANO, Stefania, VITAGLIANO, Donata, CIUFFREDA, Loreta Pia, COSTANTINO, Sara, MORGILLO, Floriana, CAPASSO, Anna, SFORZA, Vincenzo, NAPPI, Anna

Volltext

MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non–Small-cell Lung Cancer von Yin, Wei, Cheng, Joanne, Tang, Zhenya, Toruner, Gokce, Hu, Shimin, Guo, Ming, Robinson, Melissa, Medeiros, L. Jeffrey, Tang, Guilin

Volltext

EMT, MET, Plasticity, and Tumor Metastasis von Bakir, Basil, Chiarella, Anna M., Pitarresi, Jason R., Rustgi, Anil K.

Volltext

Targeting MET in Lung Cancer: Will Expectations Finally Be MET? von Drilon, Alexander, Cappuzzo, Federico, Ou, Sai-Hong Ignatius, Camidge, D. Ross

Volltext

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC von Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F, Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C, Lo, Ying-Chun, Li, Yvonne Y, Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S D, Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P, Albayrak, Adem, Cherniack, Andrew D, Price, Kristin S, Fairclough, Stephen R, Nishino, Mizuki, Sholl, Lynette M, Oxnard, Geoffrey R, Jänne, Pasi A, Awad, Mark M

Volltext

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro von Fujino, Toshio, Kobayashi, Yoshihisa, Suda, Kenichi, Koga, Takamasa, Nishino, Masaya, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Tomizawa, Kenji, Takemoto, Toshiki, Mitsudomi, Tetsuya

Volltext

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations von Caparica, Rafael, Yen, Cheng Tzu, Coudry, Renata, Ou, Sai-Hong Ignatius, Varella-Garcia, Marileila, Camidge, D. Ross, de Castro, Gilberto

Volltext

C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression von Bhardwaj, Vikas, Zhan, Yanai, Cortez, Maria Angelica, Ang, Kie Kian, Molkentine, David, Munshi, Anupama, Raju, Uma, Komaki, Ritsuko, Heymach, John V., Welsh, James

Volltext

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models von Gavine, Paul R., Ren, Yongxin, Han, Lu, Lv, Jing, Fan, Shiming, Zhang, Wei, Xu, Wen, Liu, Yuan Jie, Zhang, Tianwei, Fu, Haihua, Yu, Yongjuan, Wang, Huiying, Xu, Shirlian, Zhou, Feng, Su, Xinying, Yin, XiaoLu, Xie, Liang, Wang, Linfang, Qing, Weiguo, Jiao, Longxian, Su, Weiguo, Wang, Q. May

Volltext

Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial von Landi, Lorenza, Chiari, Rita, Tiseo, Marcello, D'Incà, Federica, Dazzi, Claudio, Chella, Antonio, Delmonte, Angelo, Bonanno, Laura, Giannarelli, Diana, Cortinovis, Diego Luigi, de Marinis, Filippo, Borra, Gloria, Morabito, Alessandro, Gridelli, Cesare, Galetta, Domenico, Barbieri, Fausto, Grossi, Francesco, Capelletto, Enrica, Minuti, Gabriele, Mazzoni, Francesca, Verusio, Claudio, Bria, Emilio, Alì, Greta, Bruno, Rossella, Proietti, Agnese, Fontanini, Gabriella, Crinò, Lucio, Cappuzzo, Federico

Volltext